Obudai Egeszseguegyi Centrum Kft.

At Obudai Egeszseguegyi Centrum Kft., researchers are evaluating new treatment strategies for patients with chronic heart failure and impaired kidney function, aiming to lower cardiovascular mortality and hospitalisations using balcinrenone/dapagliflozin.

• Combination therapy with balcinrenone/dapagliflozin for heart failure
• Survodutide efficacy on major adverse cardiovascular events
• Cardiovascular safety assessment of novel agents in overweight adults

The studies seek to improve outcomes for high‑risk cardiovascular patients through innovative drug comparisons.

The centre conducts trials focused on inflammatory bowel conditions such as ulcerative colitis and Crohn’s disease, assessing novel agents for endoscopic healing and clinical remission.

• 12‑week efficacy of a new biologic versus mirikizumab in ulcerative colitis
• Combination therapy evaluation in Crohn’s disease
• Maintenance therapy assessment for ulcerative colitis

These investigations aim to provide patients with more effective and faster‑acting treatment options for chronic gut inflammation.

Investigators are testing advanced immunomodulators in adults with moderate to severe plaque psoriasis, with the goal of achieving higher clearance rates than existing standards using agents such as JNJ‑77242113.

• Efficacy of JNJ‑77242113 compared with placebo
• Head‑to‑head comparison with ustekinumab
• Safety profiling of new biologic agents

The work supports the development of next‑generation therapies for immune‑mediated skin disease.

Research at the Budapest site includes studies on obesity, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease, exploring combinations that improve weight loss, glycemic control, and liver health such as elecoglipron.

• Combination of elecoglipron with dapagliflozin for glycemic management
• BI 456906 evaluation for cardiovascular safety in overweight individuals
• SYNERGY‑Outcomes master protocol for steatotic liver disease

These trials target the growing burden of metabolic disorders by testing therapies that address multiple risk factors simultaneously.